Empagliflozin has shown to reduce the risk of cardiovascular death in diabetics with cvd, while canagliflozin has an increased risk of bone fractures and leg/foot amputations. Would any prescribers initiate canagliflozin over Empagliflozin knowing this? Do you think canagliflozin will fall off the market eventually?